drugset / Trial / NCT00869089
Safety and Efficacy of CC-10004 for Prurigo Nodularis
Phase 2
Completed
5 enrolled
University Hospitals Cleveland Medical Center
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will include: * Study period up to 7 months. * Office visits monthly lasting approximately 1 hour. * Blood Draws. * Oral medication that is taken 2 times daily. * Photographs and biopsies if agreed.
Timeline
- Start
- 2008-09
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | Oral |